CervoMed

CRVOPhase 2

Founded 2014cervomed.com

CervoMed (formerly EIP Pharma) is a US-based biotech focused on age-related neurological disorders, operating on the premise that early-stage neurodegeneration is driven by reversible synaptic dysfunction caused by neuroinflammation. The company's lead asset, neflamapimod, has demonstrated positive Phase 2b data in Dementia with Lewy Bodies and has obtained FDA alignment for a Phase 3 trial. With an experienced leadership team including former Vertex and Biogen executives, CervoMed is advancing a targeted approach to treat DLB patients without Alzheimer's co-pathology, addressing a significant unmet need in the second most common progressive dementia.

Founded

2014

Focus

Small Molecules

CRVO · Stock Price

USD 48600.001942650.00 (-97.56%)

Historical price data

AI Company Overview

Technology Platform

Oral small molecule inhibitors targeting p38 alpha kinase to reverse synaptic dysfunction in early-stage neurodegenerative diseases, with biomarker-driven patient selection focusing on those without Alzheimer's co-pathology.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
Neflamapimod + Placebo	Dementia With Lewy Bodies	Phase 2
Neflamapimod + Placebo	Moderate to Severe Acute Ischaemic Stroke	Phase 2
neflamapimod	Dementia With Lewy Bodies (DLB)	Phase 2
Neflamapimod + Placebo	Nonfluent Variant Primary Progressive Aphasia (nfvPPA)	Phase 2

Funding History

Total raised: $10M

PIPE$10MUndisclosedJul 15, 2023

Opportunities

CervoMed has significant growth opportunities in addressing the large unmet need in Dementia with Lewy Bodies, the second most common progressive dementia.

Success in DLB could enable expansion into other neurodegenerative indications like frontotemporal dementia and stroke recovery, leveraging the same p38 alpha inhibition mechanism.

The biomarker-driven approach targeting patients without Alzheimer's co-pathology could support premium pricing and faster adoption if clinical differentiation is demonstrated.

Risk Factors

Key risks include clinical trial failure in Phase 3 development, regulatory challenges in subjective neurological endpoints, financial constraints requiring additional capital raises, and competitive pressure from larger pharmaceutical companies.

The precision medicine approach focusing on biomarker-defined subpopulations could limit market size if the biomarker strategy doesn't perfectly align with treatment response.

Competitive Landscape

CervoMed competes in the crowded neurodegenerative disease space but differentiates through its focus on synaptic dysfunction rather than protein aggregation, specific p38 alpha inhibition mechanism, and biomarker-driven patient selection in DLB. The company faces competition from larger pharma developing Alzheimer's and Parkinson's therapies that may have crossover applications, but has less direct competition in specifically targeting early-stage DLB patients without Alzheimer's co-pathology.